

Special Issue

Vaccines to Reduce Antimicrobial Resistance to Bacterial Pathogens

Message from the Guest Editors

The rise of antimicrobial resistance has led to the inefficacy of drugs and persistent infections, which consequently increase the risk of severe illness and the spread of disease. To combat antimicrobial resistance, an integrated approach that includes vaccines and antibiotics is needed. Vaccines play a crucial role in preventing infections caused by resistant bacteria, thereby reducing the reliance on antibiotics and slowing the spread of resistance. This Special Issue aims to provide an overview of advancements in the development of bacterial vaccines targeting antimicrobial-resistant pathogens. The scope of this Special Issue includes the following topics: (i) novel technologies and approaches to the production of bacteria vaccines, (ii) vaccination-induced immune responses, (iii) mucosal vaccines and vaccination, and (iv) the use of vaccines as tools for combating antimicrobial resistance. We welcome the submission of research papers, short communications, and reviews related to these topics.

Guest Editors

Dr. Miriam Moscoso

Dr. Astrid Pérez

Dr. Eva Gato

Deadline for manuscript submissions

28 February 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/213927

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).